Evidence map›Paper›PMID 21388194›Full record

ArticleBioconjugate chemistry2011

Novel method to label solid lipid nanoparticles with 64cu for positron emission tomography imaging.

Erica Andreozzi, Jai Woong Seo, Katherine Ferrara, Angelique Louie

Open access · greenAbstract read
In one paragraph

Article in Bioconjugate chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 77 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Nanomaterial Probes for Nuclear Imaging.Nanomaterials (Basel, Switzerland) · 2022
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Kinetic quantification of protein polymer nanoparticles using non-invasive imaging.Integrative biology : quantitative biosciences from nano to macro · 2013
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Erica AndreozziDepartment of Biomedical Engineering, University of California , Davis, California, United States.
Jai Woong Seo
Katherine Ferrara
Angelique Louie
University of California, Davis · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI PRIMO N. LARA · 2002 to 2026
$84.9M
Ultrasound Imaging and Local Drug Delivery in TumorsR01CA103828 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI FERRARA, KATHERINE W · 2004 to 2013
$10.4M
Multimodal mPET &mMRI Imaging InstrumentationR01EB000993 · NIBIB · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI CHERRY, SIMON R, JACOBS, RUSSELL E · 2004 to 2013
$9.2M
Engineering Approaches to Molecular Imaging TrainingT32EB003827 · NIBIB · UNIVERSITY OF CALIFORNIA DAVIS · PI FERRARA, KATHERINE W · 2004 to 2013
$1.6M
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA103828NCI NIH HHS R01CA103828NIBIB NIH HHS EB000993-06NIBIB NIH HHS EB003827NIBIB NIH HHS R01 EB000993NIBIB NIH HHS T32 EB003827
6 · The paper itself

Abstract

Solid lipid nanoparticles (SLNs) are submicrometer (1-1000 nm) colloidal carriers developed in the past decade as an alternative system to traditional carriers (emulsions, liposomes, and polymeric nanoparticles) for intravenous applications. Because of their potential as drug carriers, there is much interest in understanding the in vivo biodistribution of SLNs following intravenous (i.v.) injection. Positron emission tomography (PET) is an attractive method for investigating biodistribution but requires a radiolabeled compound. In this work, we describe a method to radiolabel SLN for in vivo PET studies. A copper specific chelator, 6-[p-(bromoacetamido)benzyl]-1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (BAT), conjugated with a synthetic lipid, was incorporated into the SLN. Following incubation with (64)CuCl(2) for 1 h at 25 °C in 0.1 M NH(4)OAc buffer (pH 5.5), the SLNs (∼150 nm) were successfully radiolabeled with (64)Cu (66.5% radiolabeling yield), exhibiting >95% radiolabeled particles following purification. The (64)Cu-SLNs were delivered intravenously to mice and imaged with PET at 0.5, 3, 20, and 48 h post injection. Gamma counting was utilized post imaging to confirm organ distributions. Tissue radioactivity (% injected dose/gram, %ID/g), obtained by quantitative analysis of the images, suggests that the (64)Cu-SLNs are circulating in the bloodstream after 3 h (blood half-life ∼1.4 h), but are almost entirely cleared by 48 h. PET and gamma counting demonstrate that approximately 5-7%ID/g (64)Cu-SLNs remain in the liver at 48 h post injection. Stability assays confirm that copper remains associated with the SLN over the 48 h time period and that the biodistribution patterns observed are not from free, dissociated copper. Our results indicate that SLNs can be radiolabeled with (64)Cu, and their biodistribution can be quantitatively evaluated by in vivo PET imaging and ex vivo gamma counting.

Indexed as

Chelating AgentsCopper RadioisotopesRadiopharmaceuticalsAnimalsCattleCell Line, TumorDogsHumansLipidsModels, MolecularMolecular StructureNanoparticlesOrganometallic CompoundsParticle SizePositron-Emission TomographySerum Albumin, BovineChelating AgentsCopper RadioisotopesLipidsOrganometallic CompoundsRadiopharmaceuticalsSerum Albumin, Bovine

Identifiers

PMID21388194
PMCPMC3086097
OpenAlexW2415854718

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.